ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

  ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

Business Wire

SAN DIEGO -- May 14, 2013

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it intends to
offer and sell, subject to market and other conditions, shares of its common
stock in an underwritten public offering. There can be no assurance as to
whether or when the offering may be completed, or as to the actual size or
terms of the offering.

Jefferies LLC and Cowen and Company, LLC are acting as the joint book-running
managers for the offering. JMP Securities LLC and Needham & Company, LLC are
acting as co-managers for the offering.

The shares of common stock described above are being offered by ACADIA
pursuant to a shelf registration statement previously filed by ACADIA with the
Securities and Exchange Commission (SEC) and declared effective by the SEC on
January 6, 2012. A preliminary prospectus supplement related to the offering
will be filed with the SEC and will be available on the SEC's website located
at Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to this offering, when available, may be
obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 12th floor, New York, NY 10022 or by telephone
at 877-547-6340 or by email at, or from
Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island
Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone: 631-274-2806,
Fax: 631-254-7140).

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that
address unmet medical needs in neurological and related central nervous system
disorders. ACADIA has a pipeline of product candidates led by pimavanserin,
which is in Phase III development as a treatment for Parkinson's disease
psychosis. ACADIA also has clinical-stage programs for chronic pain and
glaucoma in collaboration with Allergan, Inc. and two advanced preclinical
programs directed at Parkinson’s disease and other neurological disorders. All
product candidates are small molecules that emanate from discoveries made at

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature
are forward-looking statements. These statements include but are not limited
to statements related to the proposed offering of common stock by ACADIA.
These statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such statements
due to various factors, including market risks and uncertainties and the
satisfaction of customary closing conditions for an offering of securities.
For a discussion of these and other factors, please refer to ACADIA’s annual
report on Form 10-K for the year ended December31, 2012 as well as ACADIA’s
subsequent filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this cautionary
statement and ACADIA undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof, except as
required by law.


ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, Executive Vice President,
Chief Financial Officer and Chief Business Officer
Lisa Barthelemy, Director of Investor Relations
(858) 558-2871
Press spacebar to pause and continue. Press esc to stop.